Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors ...

If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company ...

Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...

Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Atypical Hemolytic Uremic Syndrome market Forecast. DelveInsight's Atypical Hemolytic Uremic Syndrome Market report offers an in-depth understanding of the ...

Novartis has streamlined its operations to concentrate solely on its Pharmaceutical ... Analysts highlight several promising assets, including Pluvicto, Scemblix, remibrutinib, Fabhalta, inalumab, and ...